You are here

P&T News

March 12

Regeneron, Sanofi offer price reductions
Sollpura didn’t meet noninferiority endpoint versus Pancreaze
Cardiovascular death, heart failure hospitalization decrease
In one case, a required postmarket surveillance study hasn’t even started

March 8

Insurers, PBMs respond by blaming drug-makers for steep prices
Injectable Trogarzo targets multidrug-resistant disease
St. Jude Medical valve aids in treatment of birth defects
A negative result in the 23andMe test doesn’t rule out increased cancer risk
Steps needed to mass-produce vaccines using cell-based and other technologies

March 6

American College of Physicians ups A1c limit to 8%
Drug is first FDA-approved PD-1 inhibitor to offer every-four-week dosing
Findings challenge common practice of increasing doses at early signs of worsening symptoms
Shorter course of therapy may increase patients’ treatment adherence
Lanadelumab reduced monthly attack rates and improved quality of life in study

March 5

Biogen, AbbVie blame reports of inflammatory brain disorders
One-time chief of Turing Pharmaceuticals may be out a Picasso
Agency cites deficiencies; Cantrell criticizes communication
Visual acuity improves among patients who receive Clearside medication

March 2

Several states report less flu activity; fatalities decrease again

March 1

Real-world evidence is attracting a lot of attention, pro and con

Pages